Antiviral Treatment for Cytomegalovirus Diseases
A special issue of Viruses (ISSN 1999-4915). This special issue belongs to the section "Viral Immunology, Vaccines, and Antivirals".
Deadline for manuscript submissions: closed (31 July 2023) | Viewed by 11591
Special Issue Editor
Special Issue Information
Dear Colleagues,
Cytomegalovirus is a beta-herpesvirus that has evolved to exist in human populations, with a seroprevalence ranging from 50% to near-universal seropositivity among adult populations worldwide. However, in special populations such as the immunocompromised host or the infected fetus, cytomegalovirus can cause viral disease, long-term disabilities, and even death. The historical mainstays of antiviral drug therapy against cytomegalovirus have included ganciclovir, valganciclovir, cidofovir, and foscarnet, but their effectiveness may be influenced by viral mutations, differences in host metabolism (pharmacokinetics/pharmacodynamics), and drug interactions in various clinical settings. Recently, new antivirals have been approved or are in Phase I-III clinical trials for CMV treatment and prevention, including letermovir and maribavir, as are emerging approaches that utilize T cell and NK cell therapies in immunocompromised hosts. Antiviral therapies are also used to mitigate the long-term neurologic consequences of congenital CMV infection, and to prevent in utero transmission among high-risk pregnant women. This Special Issue will highlight current and emerging treatments against CMV infection and specific therapeutic issues relevant to various at-risk patient groups.
Dr. Masako Shimamura
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
